Journal article
Abstract 1424: Preclinical development of TAC01-CD19, a CD19 specific T-cell Antigen Coupler (TAC) therapy for the treatment of CD19-positive B cell malignancies
Abstract
Abstract
Background: The T cell antigen coupler (TAC) is a chimeric receptor co-opting the natural TCR receptor signaling complex to target tumor antigens in an MHC-independent manner (Helsen et. al., Nat. Comm. 2018). TAC engineered T cells mediate biological effects that are distinct from conventional chimeric antigen receptors (CARs) and may offer safety advantages due to greater target selectivity and no detectable …
Authors
Helsen CW; Hayes D; Hammill J; Aarts C; Bader A; Rill D; Bramson J
Journal
Cancer Research, Vol. 79, No. 13_Supplement, pp. 1424–1424
Publisher
American Association for Cancer Research (AACR)
Publication Date
July 1, 2019
DOI
10.1158/1538-7445.am2019-1424
ISSN
0008-5472